Proteinuria reduction: mandatory consideration or option when selecting an antihypertensive agent?

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Proteinuria, including microalbuminuria, is a significant risk factor for cardiovascular disease and kidney disease progression.
• Hypertension increases proteinuria risk, necessitating antihypertensive treatments that also reduce protein excretion.

Purpose of the Study:

• To evaluate the role of proteinuria reduction in antihypertensive treatment selection.
• To assess the efficacy of different antihypertensive agents in reducing proteinuria.

Main Methods:

• Review of observational studies and intervention trials.
• Analysis of clinical trial data on antihypertensive agents, including those blocking the renin-angiotensin-aldosterone system (RAAS).
• Comparison of nondihydropyridine calcium channel blockers with ACE inhibitors and dihydropyridine calcium channel blockers in type 2 diabetics.

Main Results:

• Lowering proteinuria in chronic kidney disease patients reduces progression to end-stage kidney disease and improves cardiovascular outcomes.
• RAAS-blocking agents are generally more effective than other antihypertensives for proteinuria reduction.
• Nondihydropyridine calcium channel blockers may be more effective than dihydropyridine calcium channel blockers in specific diabetic populations.

Conclusions:

• Proteinuria reduction should be a mandatory consideration when selecting antihypertensive regimens.
• Evidence supports the use of RAAS inhibitors and potentially nondihydropyridine calcium channel blockers for managing proteinuria.
• Integrated management of hypertension, proteinuria, and cardiovascular/kidney disease is essential.